Sign In
Last checked at 
10 Oct 2012 10:06
ο»Ώ
Β
Β
Β
Β
Β
Hikma Pharmaceuticals PLC
Voting Rights and Capital
Β
LONDON, 10 October 2012, Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) notifies the market that its capital consists of 196,971,407 ordinary shares with voting rights. There are no shares held in treasury.
Β
The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FSA's Disclosure and Transparency Rules.
Β
- ENDS -
Β
Enquiries
Β
Hikma Pharmaceuticals PLC | Β | |
Peter Speirs Company Secretary Β | +44 20 7399 2760 Β | |
Β | ||
Β
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and nonβbranded generic and inβlicensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2011, Hikma achieved revenue of $918.0 million and profit attributable to shareholders of $80.1 million.
Follow the stocks
